-
公开(公告)号：WO2023080189A1
公开(公告)日：2023-05-11
申请号：PCT/JP2022/041114
申请日：2022-11-04
Applicant: 興和株式会社
Abstract: ＳＡＲＳ－ＣｏＶ－２感染に基づく疾患、ＣＯＶＩＤ－１９の予防及び／又は治療のための新たな医薬を提供することを課題とする。 本発明は、（ａ）平均粒子径０．５～１０μｍのセファランチン粉末及び（ｂ）平均粒子径１～２００μｍの乳糖を含有するカプセル剤を気密包装体に収容してなる医薬品であって、当該気密包装体内には不活性ガス及び／又は脱酸素剤が封入されてなる医薬品に関する。
-
-
公开(公告)号：WO2022266251A1
公开(公告)日：2022-12-22
申请号：PCT/US2022/033670
申请日：2022-06-15
Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventor： MARINKOVICH, M. Peter , BUTTE, Atul Janardhan , NASRALLAH, Mazen , WINGE, Marten CG
IPC: A61K31/498 , A61K31/4741
Abstract: Methods of treatment for psoriasis, and compositions for use in such methods are provided, utilizing repositioned drugs identified as anti-psoriasis agents.
-
公开(公告)号：WO2022159666A1
公开(公告)日：2022-07-28
申请号：PCT/US2022/013257
申请日：2022-01-21
Applicant: NORTHWESTERN UNIVERSITY
Inventor： KIYOKAWA, Hiroaki , MISHRA, Rama, K. , LUAN, Chi-Hao
IPC: A61K31/473 , A61K31/4741 , A61K31/4745
Abstract: Disclosed herein are compounds, compositions, and methods for inhibiting HECT E3 ubiquitin ligases. In some embodiments, the compounds are formulated as a pharmaceutical composition and administered to a subject in need thereof. In some embodiments, the subject in need thereof is diagnosed with a neurological disease or a cancer characterized by increased or ectopic HECT E3 ligase activity.
-
公开(公告)号：WO2021192726A1
公开(公告)日：2021-09-30
申请号：PCT/JP2021/005541
申请日：2021-02-15
Applicant: 学校法人東京医科大学
Inventor： 稲津 正人
IPC: A61K31/4741 , A61K31/472 , A61P35/00 , A61P43/00
Abstract: 抗がん剤として使用できる新たな薬剤の提供を目的とする。 本発明のコリン取り込み抑制剤は、細胞に対するコリンの取り込みを抑制する抑制剤であり、下記式（１）で表されるイソキノリン化合物またはその誘導体を含むことを特徴とする。
-
Patent Agency Ranking
公开(公告)号：WO2020028757A1
公开(公告)日：2020-02-06
申请号：PCT/US2019/044809
申请日：2019-08-02
Applicant: TRUSTEES OF BOSTON UNIVERSITY
Inventor： SCHAUS, Scott Edward , HANSEN, Ulla , CHIN, Hang Gyeong
IPC: A61K31/4704 , A61K31/4741 , A61P35/00
Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
-
公开(公告)号：WO2020006631A1
公开(公告)日：2020-01-09
申请号：PCT/CA2019/050915
申请日：2019-07-03
Applicant: ALGERNON PHARMACEUTICALS INC.
Inventor： WILLIAMS, Mark
IPC: A61K31/53 , A61K31/136 , A61K31/196 , A61K31/4184 , A61K31/4468 , A61K31/4741 , A61K31/519 , A61K31/522 , A61P1/16
Abstract: Cepharanthine, Repirinast, Ifenoprodil Hemitartrate, Bromantane, Actarit, Lobenzarit, Irsogladine, Istradefylline, Trapadil, Bemithyl, and are used for treating or prophylaxis of lobular inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in a subject.
-
8.发明申请
公开(公告)号：WO2020000092A1
公开(公告)日：2020-01-02
申请号：PCT/CA2019/050881
申请日：2019-06-25
Applicant: ALGERNON PHARMACEUTICALS INC.
Inventor： WILLIAMS, Mark
IPC: A61K31/196 , A61K31/13 , A61K31/4184 , A61K31/44 , A61K31/445 , A61K31/4741 , A61K31/519 , A61K31/522 , A61P13/12
Abstract: Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.
-
公开(公告)号：WO2019226491A1
公开(公告)日：2019-11-28
申请号：PCT/US2019/032926
申请日：2019-05-17
Applicant: CONSTELLATION PHARMACEUTICALS, INC.
Inventor： CÔTÉ, Alexandre , KHANNA, Avinash , MOINE, Ludivine
IPC: C07D491/056 , A61K31/4741 , A61P35/00
Abstract: Provided are novel compounds of Formula (I): Formula (I); and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
-
公开(公告)号：WO2019182944A1
公开(公告)日：2019-09-26
申请号：PCT/US2019/022686
申请日：2019-03-18
Applicant: ALLCRON PHARMA INC.
Inventor： RAJASEKARAN, Ayyappan , SWANSON, Jon , KANE, Peter , FOSTER, Julia
IPC: C07D491/056 , A61K31/4741 , A61P35/00
Abstract: Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.
-
-
-
-
-
-
-
-
-
Search Results
373
records
(took 0.036 seconds)
